Therapeutic Areas: Oncology | Gastroenterology | Endocrinology | Family Medicine
A listing of Pancreatic Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
State
Country
Birmingham : University of Alabama Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Mobile : University of South Alabama Updated
Muscle Shoals : Northwest Alabama Cancer Center
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Tucson : Arizona Cancer Center Updated
Little Rock : University of Arkansas for Medical Sciences Updated
Duarte : City of Hope Updated
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgically Resected Pancreatic Cancer
SWOG S1115: Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients with Metastatic Pancreatic Cancer After Prior Chemotherapy
Los Angeles : Cedars-Sinai Medical Center Updated
Palo Alto : Stanford Cancer Center Updated
Sacramento : Sutter Institute for Medical Research Updated
San Francisco : California Pacific Medical Center Updated
Aurora : University of Colorado Denver
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
Aurora : University of Colorado Updated
Stamford : Stamford Hospital Updated
Newark : Helen F. Graham Cancer Center
Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers
Washington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Washington : Georgetown University Updated
Boca Raton : Boca Raton Hospital Updated
Fort Lauderdale : Broward Oncology Associates
Gainesville : University of Florida Updated
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Jacksonville : Mayo Clinic Updated
Jacksonville : Baptist Cancer Institute
Lakeland : Lakeland Regional Cancer Center Updated
Miami : University of Miami Updated
Miami : University of Miami
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
New Port Richey : Pasco Pinellas Cancer Center
Sarasota : Florida Cancer Specialists
Safety and Tolerability Study in Solid Tumors
Tampa : MOFFITT Updated
Tampa : USF Tampa General Updated
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
Savannah : Memorial University Medical Center Updated
ACOSOG Z5041 : A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma.
RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.
Arlington Heights : Illinois Cancer Specialists Updated
Chicago : University of Chicago Medical Center
Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer
Chicago : Northwestern University Updated
Evanston : Northshore University Health Systems Updated
Galesburg : Medical and Surgical Specialists
Harvey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Skokie : Edward H. Kaplan, MD and Associates Updated
Skokie : Hematology / Oncology of the North Shore
Goshen : IU Health Goshen Cancer Center
Indianapolis : Investigative Clinical Research of Indiana, LLC Updated
Indianapolis : Indiana University Updated
Ames : McFarland Clinic
Iowa City : University of Iowa Updated
Westwood : University of Kansas Cancer Center Updated
Louisville : University of Louisville Updated
Baton Rouge : Mary Bird Perkins Cancer Center Updated
Baton Rouge : Mary Bird Perkins Cancer Center
New Orleans : Ochsner Cancer Institute Updated
Baltimore : University of Maryland Updated
Boston : Massachusetts General Hospital Dept. of Mass General Hospital
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Boston : Massachusetts General Hospital Updated
Boston : Beth Israel Deaconess Medical Center Updated
Boston : Dana-Farber Cancer Institute Updated
Boston : Massachusetts General Hospital Cancer Center
Safety Study of MGA271 in Refractory Cancer
Burlington : Lahey Clinic Updated
Ann Arbor : University of Michigan Updated
Detroit : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Detroit : Karmanos Cancer Institute
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Royal Oak : Beaumont Hospital Updated
Minneapolis : Virginia Piper Cancer Institute Updated
Rochester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Rochester : Mayo Clinic Updated
Columbia : University of Missouri Updated
Kansas City : Research Medical Center
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
St. Louis : Washington University Updated
Lincoln : Southeast Nebraska Hematology & Oncology Consultants
Omaha : University of Nebraska Medical Center Updated
Jersey City : CarePoint Health Research Institute Updated
Conducting Pancreatic Cancer Clinical Research for the Future
Albuquerque : University of New Mexico Updated
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
A Phase 2 Study of REOLYSIN in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
Bronx : Biomedical Research Alliance of New York
Pancreatic Cancer - Adults
Lake Success : Arena Oncology Associates
New York : Memorial Sloan Kettering Cancer Center MSKCC - SC
New York : Mount Sinai Medical Center Updated
New York : Weill Cornell/New York Presbyterian Hospital
New York : Memorial Sloan Kettering Cancer Center
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Staten Island : Richmond University Medical Center
Durham : Duke University Medical Center Updated
Winston-Salem : Wake Forest Baptist Health Comprehensive Cancer Center Updated
Cincinnati : University of Cincinnati Updated
Cleveland : University Hospitals Case Western Updated
Cleveland : University Hospitals
Columbus : Ohio State University Updated
Oklahoma City : University of Oklahoma Updated
Oklahoma City : University of Oklahoma
Oklahoma City : Stephenson Cancer Center
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Portland : Oregon Health and Science University Updated
Bethlehem : St. Luke's Hospital and Health Network Updated
Dunmore : Hematology and Oncology Associates of NE PA
Philadelphia : Thomas Jefferson University Updated
Philadelphia : Fox Chase Cancer Center Updated
Philadelphia : University of Pennsylvania Updated
Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center
Pittsburgh : University of Pittsburg Medical Center Updated
Providence : Roger Williams Medical Center Updated
Greenville : Cancer Center of the Carolinas Updated
Memphis : The West Clinic
Nashville : Sarah Cannon Research Institute
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Dallas : University of Texas Southwestern Medical Center Updated
Garland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Houston : UT MD Anderson Cancer Center
Chemoradiation-Induced Nausea and Emesis: Quality of Life
Houston : Baylor College of Medicine Updated
Houston : Ben Taub Hospital Updated
Houston : The Methodist Hospital Updated
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Houston : Oncology Consultants
Lubbock : Joe Arrington Cancer Research and Treatment Center Updated
San Antonio : University of Texas Health Sciences Updated
The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Tyler : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman UT
Charlottesville : University of Virginia Updated
Lynchburg : Lynchburg Hematology-Oncology Clinic, Inc. Updated
Richmond : Virginia Commonwealth University Updated
Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Seattle : University of Washington- Seattle Cancer Center Alliance Updated
Tacoma : Northwest Medical Specialties
Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Morgantown : West Virginia University - Clinical Trials Research Unit
ACOSOG-Z5041: Ph2 of Neoadjuvant and Adjuvant Gemcitabine Hydrochloride and Erlotinib Hydrochloride in pts + Resectable Adenocarcinoma of the Pancreas Undergoing Pancreatectomy.
Green Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Green Bay : Vince Lombardi Cancer Clinic Updated
Madison : University of Wisconsin Updated
Box Hill : Box Hill Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Camperdown : Royal Prince Alfred Hospital
Heidelberg : The Austin Hospital
Graz : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : Research Site
St Poelten : Research Site
Vöcklabruck : Research Site
Wels : Research Site
Wien : Research Site
Wien :
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Aalst : Research Site
Bonheiden : Research Site
Brasschaat : Research Site
Brugge : Research Site
Brussels : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Edegem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Eupen : Research Site
Gilly : Research Site
Leuven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mechelen : Research Site
Namur : Research Site
Oostende : Research Site
Sint-Niklaas : Research Site
Verviers : Research Site
Calgary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Toronto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Beijing : Beijing Cancer Hospital
SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer
Shanghai : Shanghai Changhai Hospital
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Tianjin : Tianjin Medical University Cancer Institute and Hospital
Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
Nicosia : Cyprus Oncology Centre
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Aix en Provence : Research Site
Aix en Provence cedex 01 : Research Site
Amiens : Research Site
Bayonne : Research Site
Besançon Cedex : Research Site
Bordeaux : Research Site
Boulogne sur Mer Cédex : Research Site
Bourg en Bresse : Research Site
Brive la Gaillarde : Research Site
Clermont Ferrand : Research Site
Clermont-Ferrand : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Colmar Cedex : Research Site
Dijon : Research Site
La Seyne Sur Mer : Research Site
Le Mans Cedex 9 : Research Site
Lomme : Hôpital Saint-Philibert
Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Longjumeau cedex 1 : Research Site
Lyon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Lyon : Hôpital Jean Mermoz
Marseille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Marseille : Research Site
Marseille : Institut Paoli Calmettes
Mont de Marsan : Research Site
Nancy : Research Site
Périgueux cedex : Research Site
Paris Cedex 20 : Research Site
Pontoise Cedex : Research Site
Pringy Cedex : Research Site
Reims : Research Site
Reims Cedex : Research Site
Rennes : Research Site
Rouen : Research Site
Saint Grégoire cedex : Research Site
Saint Quentin : Research Site
Soissons Cedex : Research Site
Soyaux : Research Site
Strasbourg : Research Site
Vichy cedex : Research Site
Villefranche Sur Saone Cedex : Research Site
Villejuif Cedex : Research Site
Augsburg : Research Site
Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Berlin : Research Site
Bremerhaven : Research Site
Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Friedrichshafen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Goslar : Research Site
Halle/Saale : Research Site
Köln : Research Site
Kassel : Research Site
Koeln :
An Observational Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Leipzig : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mannheim : Research Site
Marburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mönchengladbach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Neunkirchen : Research Site
Reutlingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Stralsund : Research Site
Würselen : Research Site
Athens : Research Site
Chania : Research Site
Marousi : Research Site
Papagou : Research Site
Thessaloniki : Research Site
Dublin : St Vicents University Hospital
Dublin : Adelaide, Meath & National Childrens Hospital,
Jerusalem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Kfar Saba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Petah Tiqva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Tel Hashomer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Tel-Aviv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Cefalù PA : Research Site
Confreria : A.O. Santa Croce e Carle, Struttura Complessa di Oncologia Medica
Monza : Azienda Ospedaliera San Gerardo Struttura Complessa Oncologia Medica
Napoli : Research Site
Novara : AOU Maggiore della Carità
Padova : Research Site
Roma : Research Site
Torino : Research Site
Verona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Gifu : Gifu University
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Onomichi : Onomichi General Hospital
Sapporo : Teine-Keijinkai Hospital
Tokyo : Research Site Updated
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Tokyo : The University of Tokyo
Tokyo : Tokyo Medical University
Tokyo : Toho University
Ube : Yamaguchi University
Bucheon : Soon Chun Hyang University School of Medicine
Cheonan : Soon Chun Hyang University School of Medicine
Daegu : Catholic University of Daegu School of Medicine
Goyang-si : NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong‐gu,
Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)
Incheon : Inha University School of Medicine
Seoul : Gangnam Severance Hospital
Suwon : Ajou University School of Medicine
Amstelveen : Research Site
Amsterdam : VU University Medical Center
Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer
Dordrecht : Research Site
Enschede : Research Site
Leiderdorp : Research Site
Purmerend : Research Site
Roosendaal : Research Site
Vlissingen : Research Site
Zutphen : Research Site
Christchurch : Christchurch Hospital
Hamilton : Waikato Hospital
Oslo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Trondheim : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Bialystok : Research Site
Gdansk : Research Site
Koszalin : Research Site
Krakow : Research Site
Lubin : Research Site
Olsztyn : Research Site
Poznan : Research Site
Walbrzych : Research Site
Wroclaw : Research Site
Alba Iulia : Research Site
Baia-Mare : Research Site
Brasov : Research Site
Bucharest : Research Site
Bucuresti : Research Site
Cluj-Napoca : Research Site
Oradea : Research Site
Ramnicu Valcea : Research Site
Targu Mures : Research Site
Timisoara : Research Site
Riyadh : National Guard Health Affairs
Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer
Outram Road : Singapore General Hospital
32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
Alicante : Hospital General de Alicante
Asturias : Medical Oncology Department, Central University Hospital of Asturias
Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Madrid : START Madrid
Madrid : Hospital Gregorio Marañon
Pozuelo De Alarcon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Valencia : Department of Medical Oncology, Hospital Universitari La Fe,
Valencia : Instituto Valenciano de Oncologia
Zaragoza : Hospital Miguel Servet
Acton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Blackburn : Royal Blackburn Hospital
Bournemouth : The Royal Bournemouth Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Bradford : Bradford Royal Infirmary
Cambridge : Cambridge University Hospitals NHS Foundation Trust Updated
HYPAZ: Hypertension Induced by Pazopanib
Cardiff : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Cardiff : Velindre Cancer Centre
Dundee : Ninewells Hospital,
Edinburgh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Guildford : Royal Surrey County Hospital
Liverpool : Royal Liverpool University Hospital
Liverpool : Clatterbridge Centre for Oncology
Liverpool : Novartis Investigative Site
London : Guy's and St Thomas' Hospital NHS Trust
London : Mount Vernon Cancer Centre
London : Guys & St Thomas Hospital
Manchester : The Christie Hospital
Middlesbrough : James Cook University Hospital
Nottingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Nottingham : Nottingham City Hospital
Peterborough : Peterbrough City Hospital, Haematology/Oncology Dept,
Sheffield : Weston Park Hospital
Skipton : Airedale General Hospital
Southampton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Sutton : The Royal Marsden NHS Trust
A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)